Company

Welcome to GSK Belgium

Belgium hosts 3 main vaccine sites for GSK (in Wavre, Rixensart and Gembloux), including the historical centre of the vaccines of the group. This makes us the largest industrial network of vaccines in the world.

Who we are

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade. Our research & development (R&D) focus is on four therapeutic areas: (1) respiratory, immunology and inflammation, (2) oncology, (3) HIV, and (4) infectious diseases.

GSK Belgium
8500
employees on our 3 sites (Wavre, Rixensart, Gembloux).
Innovation and R&D
1.3 billion
€ invested in research and development in Belgium in 2025.
Vaccines
> 160
vaccines exported to > 160 countries in 2025.
GSK dark mode static background

Ahead together

Scientist pouring a liquid into a machine

Innovation

group of children

Responsibility

Un scientifique écrit sur une feuille dans un laboratoire

Clinical trials

Bloodcells Anaemia illustration

Our global "Behind the science" magazine

Discover and read our latest innovations in our global "Behind the science" magazine.